Summary
A healthy diet shapes a healthy mind. Diet quality has a strong association with brain health. Diet influences the onset and consequences of neurological diseases, and dietary factors may influence mental health at individual and population level. The link between unhealthy diet, impaired cognitive function and neurodegenerative diseases indicates that adopting a healthy diet would ultimately afford prevention and management of neurological diseases and brain aging. Neurodegenerative diseases are of multifactorial origin and result in progressive loss of neuronal function in the brain, leading to cognitive impairment and motoneuron disorders. The so-called Mediterranean diet (MedDiet) with its healthy ingredients rich in antioxidant, anti-inflammatory, immune, neuroprotective, antidepressant, antistress and senolytic activity plays an essential role in the prevention and management of neurological diseases and inhibits cognitive decline in neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases. The MedDiet also modulates the gut-brain axis by promoting a diversity of gut microbiota. In view of the importance of diet in neurological diseases management, this review focuses on the dietary components, natural compounds and medicinal plants that have proven beneficial in neurological diseases and for brain health. Among them, polyphenols, omega-3 fatty acids, B vitamins and several ayurvedic herbs have promising beneficial effects.
Keywords: Neurological diseases, Neurodegenerative diseases, Dietary supplements, Mediterranean diet, Ayurvedic herbs
Citation
How to cite this article: Naureen Z, Dhuli K, Medori MC, Caruso P, Manganotti P, Chiurazzi P, Bertelli M. Dietary supplements in neurological diseases and brain aging. J Prev Med Hyg 2022;63(suppl.3):E174-E188. https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2759
Introduction
Neurodegenerative diseases (NDs) involve a progressive loss of neuronal activity, resulting in impairment of cognitive function. They have genetic and epigenetic etiology and are increasing at an alarming rate. For instance, 17.2 million people worldwide are suffering from NDs such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), Huntington’s disease (HD) and dementia [1, 2]. As the symptoms appear only when neurological degeneration has reached an advanced stage, the prevention of NDs and the search for new therapeutic agents is a challenge. Although the mechanisms of NDs are multifactorial and complex, they share common pathways, such as oxidative stress, inflammation, mitochondrial dysfunction and intracellular Ca2+ overload. In addition, cross talk between these multiple pathways often makes therapeutic intervention less effective.
The brain is highly sensitive to oxidative stress and increased reactive oxygen species produced during neuroinflammatory processes. As the antioxidant defence system has low activity in the brain, increased oxidative stress results in NDs and aging [3]. Genetic and epigenetic factors greatly influence the onset and development of these disorders, while nutrition and metabolism play a key role in the manifestation of epigenetic modifications of DNA in the central nervous system [4-5]. Bioactive ingredients in food and gut microbiota can greatly influence DNA methylation in the adult central nervous system, indicating a role of diet and dietary components in NDs [6]. The so-called Mediterranean diet (MedDiet) is currently regarded as the healthiest diet in the world. It includes daily intake of whole grains, vegetables, fruit, legumes, white meats, fish, nuts, olives and olive oil. Rich in antioxidants, fibre, vitamins, minerals, phytosterols, probiotics, omega-3, and omega-6 fatty acids, it promotes human health and wellbeing. The MedDiet has been associated with improvements in overall health, prevention of cancer, maintenance of a healthy cardiovascular system and metabolism, and with preventing, alleviating and slowing neurological disorders (Fig. 1).
Fig. 1.
Effects of dietary components of Mediterranean diet in neurodegenerative diseases and cerebral aging.
Clinical studies on efficacy of MedDiet in major neurodegenerative disorders
Several studies have evaluated the efficacy of the MedDiet in prevention and management of neurodegenerative disorders (Tab. I). These studies inferred that following the MedDiet not only decreases the incidence of NDs but also improves overall cognitive function and hampers the onset and progress of decline caused by NDs and cerebral aging.
Tab. I.
Clinical studies demonstrating effect of MedDiet on ND progression.
Neurological conditions | Description | Study type | Participants | Duration | Findings | Reference |
---|---|---|---|---|---|---|
Alzheimer’s disease | Formation of widespread extracellular amyloid plaques and intraneuronal neurofibril tangles in the brain (Reitz and Mayeux, 2014), a major cause of dementia | Follow-up study | 70 subjects with normal cognitive function, age 30-60 years | 3 | Not following MedDiet was correlated with progressive AD abnormalities | [7] |
Cohort studies | 1393 normal and 482 with mild cognitive impairment, age 76.7-77.5 years | 4.5 | Following MedDiet reduced risk of cognitive impairment and AD | [8] | ||
Dementia | Loss of cognitive function due to brain aging or neurodegenerative diseases | Longitudinal | 1865 (41%M) patients with dementia, mean age 73 years | 1.4 | 10% decrease in dementia on MedDiet. Cereals shown to have positive impact on mental performance | [9] |
Cross sectional | 52 subjects with normal cognitive function | - | Low intake of rice and higher intake of milk and soybean reduced risk of dementia | [10] | ||
Huntington’s disease | a rare, hereditary condition that causes progressive neurodegeneration | Prospective | 211 patients with expanded CAG repeats | 3.4 | Diet and high energy intake may delay onset | [11] |
Parkinson’s disease (PD) | Neuronal degeneration, dopaminergic loss. PD symptoms include tremors, motoneuron changes, cognitive decline, dementia and loss of muscle strength (Gratwicke et al., 2015) | Population-based cohort | 1731 (41% male) PD-free individuals, age 65 and over | - | MedDiet lowered probability of prodromal PD in elderly people | [12] |
Amyotrophic lateral sclerosis (ALS) | Degeneration of brainstem and spinal cord motoneurons resulting in progressive muscle atrophy, paralysis and respiratory failure (Oh et al., 2015) | Cross sectional baseline analysis | 302 patients with a history of ALS symptoms of 18 months or less | - | Better function associated with antioxidants and with carotenes in fruit and vegetables | [13] |
Multiple sclerosis | Demyelination of nerve fibres and myelin sheaths, affecting the optic nerves, brain and spinal cord | Survey | 396 | - | MedDiet reduces risk of relapses | [14] |
Animal studies and clinical trials have shown that the MedDiet has anti-inflammatory, antioxidant and free radical-scavenging properties that alleviate or mitigate neurotoxicity and neurodegeneration (Tab. II).
Tab. II.
Antioxidant and anti-inflammatory nutrients of the Mediterranean diet used in animal and human studies.
MedDiet component | Nutrient | Study design | Study population | Proposed antioxidant activity | References |
---|---|---|---|---|---|
Extra virgin olive oil | Total polyphenol fraction of olive oil and hydroxytyrosol. | In vitro | Endothelial cells and murine myoblasts | Redox potential enhanced by increasing glutathione levels and free radical scavenging | [15,16] |
Hydroxytyrosol and tyrosol | Randomized | Male Wistar rats | Hydroxytyrosol and tyrosol activate GSH, reduce lipid peroxidation, restore glutathione balance in liver | [17] | |
Extra virgin olive oil, oleuropein aglycone | Randomized | TgCRND8 mice | Inflammation and neurotoxicity reduced by induction of autophagy and recovery of lysosome system | [18] | |
Fish and dairy | B-vitamin folate (vitamin B9) and vitamin B12 | Transverse | ALS patients | Less inflammatory damage and oxidation, improvement in myocytic atrophy | [19] |
Citrus and green tea | Phytochemicals, triterpenoids, resveratrol | Randomized clinical | SOD1 (G93A) mice | Increased SIRT and AMPK resulting in enhanced survival of motor neurons Resveratrol treatment reduces activation of NF-kB pathway in LPS-activated microglia and stabilizes autophagic flux | [20] |
Diet enriched with oily fish, seafood, dairy, nuts, vegetables, fruit and eggs | Docosahexaenoic acid (DHA) | Transverse | BV-2 murine microglial cells | Unsaturated fatty acid-based decrease in toxic effects of 7-ketocholesterol | [21] |
MedDiet and depression
Increasing evidence suggests that depression, the foremost global cause of disability, is a subtle neurological disorder [22, 23]. Besides other therapies, diet may be useful for improving overall mental health and relieving stress and anxiety. The MedDiet, rich in vitamins, minerals, antioxidants, healthy fats and proteins, reduces the risk of depression [24]. Research-based evidence suggests that dietary measures can be an adjunctive treatment for mental disorders. For instance, a healthy diet has been tested clinically in two different trials for its effects on symptoms and remission rates of depression, showing promising results [25, 26]. As many as 37 studies have reported a reduction in symptoms of depression in groups of persons on diets rich in polyphenols [27]. An observational study also revealed that following the MedDiet was crucial for reducing depressive outcomes in overweight patients with metabolic syndrome [28]. Vicinanza et al. (2020) reported a positive impact of the MedDiet on mental health in elderly patients with multimorbidity [29]. They also observed that the diet prevented symptoms of depression in these patients, promoting healthy aging. Yet another promising clinical study named PREDI-DEP is underway to assess the MedDiet supplemented with extra virgin olive oil or nuts for precluding relapse of unipolar depression [30]. Diet plays an important role in shaping behaviour and modulating mood (Tab. III). For instance, omega-3 essential fatty acid supplements alleviated symptoms of bipolar disorder in 30 patients [31].
Tab. III.
Effect of dietary components and regimes on mood and psychological disorders.
Dietary components/regimes | Effect on mood | Study type | Participants | Reference |
---|---|---|---|---|
Vitamin D | Improved mood | Double-blind placebo-controlled | 44 healthy volunteers | [22] |
Vitamins, minerals and essential fatty acids | Reduction in antisocial behaviour | Double-blind, placebo-controlled | 231 young adult prisoners | [32] |
Tryptophan depletion | Worsening of mood in seasonal affective disorder/winter type (SAD) | Randomized, balanced, double-blind crossover | 11 SAD patients with recurrent episodes of winter depression | [33] |
Folic acid therapy | Improved intellectual function | - | 16 patients with impaired intellectual function | [34, 35] |
Folic acid deficiency | Increased depression, impaired cognitive function, impaired abstract thinking | - | 260 healthy subjects 60 to 94 years old | [36] |
Omega 3 fatty acids | Improved short-term course of illness in bipolar disorder | Placebo controlled | 30 patients with bipolar disorder | [23] |
Traditional vs western diet | Traditional diet reduced odds in bipolar disorder | Epidemiological cohort study | 23 women with bipolar disorder and 691 normal subjects | [31] |
Effect of natural compounds and medicinal plants on neurological disorders
Several medicinal plants and natural compounds have been deployed to prevent or alleviate neurological diseases and symptoms in vivo and in clinical trials. Here we discuss important natural compounds that can be obtained from dietary sources or nutritional supplements and that mediate various aspects of practical utility in the management of neurodegenerative disorders.
N-ACETYLCYSTEINE (NAC) IN NEUROLOGICAL DISORDERS
N-acetylcysteine (NAC) is a mucolytic thiol known for its ability to alleviate stress and mediate the impacts of toxicity, infections and inflammatory conditions by supporting the body’s antioxidant and nitric oxide systems [37]. It crosses blood brain barrier (BBB) and is a precursor of l-cysteine and reduced glutathione GSH, as well as a source of sulfhydryl groups in cells. It scavenges free radicals and interacts with reactive oxygen species (ROS) [38]. It has a multifaceted mode of action, acting as a drug, a xenobiotic and a cytoprotectant. The effects of NAC on various neurological and neurodegenerative diseases are summarized in Table IV.
Tab. IV.
Mechanism of action of NAC in different neurological disorders.
Disease | Mechanism | References |
---|---|---|
Unverricht–Lundbor type SCD, tardive dyskinesia, myoclonus epilepsy | Antioxidant effect by scavenging free-radicals and enhancing glutathione | [39] |
Multiple sclerosis | Scavenges free-radicals and inhibits TNF toxicity | [40] |
Amyotrophic lateral sclerosis | Enhances glutathione peroxidase and free-radical scavenging | [41] |
Parkinson’s disease | Enhances glutathione and free-radical scavenging | [42] |
Huntington’s disease | Scavenges free radicals and prevents mitochondrial dysfunction | [40] |
Alzheimer’s disease | Boosts glutathione levels | [43] |
Focal cerebral ischemia | Enhances glutathione levels, improves microcirculation and tissue oxygenation, inhibits NOS and regenerates endothelium-derived relaxing factor | [44] |
EFFECTS OF PHOSPHOLIPIDS ON NEUROLOGICAL CONDITIONS
The brain and nervous system have a more diverse lipid composition than the rest of the body, showing a predominance of phospholipids [45]. Phospholipids occur in varying concentrations in the brain, e.g. 31 nmol/mg phosphatidylcholine, 54 nmol/mg phosphatidylethanolamine, 8 nmol/mg phosphatidylserine and 5 nmol/mg of phosphatidylinositol [46]. Sphingomyelin levels in the hippocampus and prefrontal cortex are similar to those of phosphatidylethanolamine in adult male rats [47]. Phospholipids also occur in the membranes of organelles such as mitochondria, endoplasmic reticulum, Golgi apparatus, peroxisomes and lysosomes, which illustrates their importance in cells. Studies have revealed that phospholipid-enriched diets can modulate cognitive processes [48] and phospholipid supplementation has been shown to increase cognitive function in a polyunsaturated fatty acid-deficient mice model and to improve memory in piglets on permanent supplements [49].
Phosphatidylserine
Phosphatidylserine (PS) is an acidic phospholipid and a natural component of brain neuronal membranes and other biological membranes. It plays a pivotal role in normal neuronal function by determining neuronal membrane surface potential and the local ionic environment [50]. Phosphatidylserine is a brain-specific nutrient [51] and activates protein kinase C (PKC) in neural membranes. It is thought to decrease in the brain with aging, leading to cognitive decline and impairment as well as lower PKC activity [52]. Phosphatidylserine functions equally well in adults, children and the elderly. For instance, in young healthy males it mitigates stress-induced activation of the hypothalamus-pituitary-adrenal axis [53]. Phosphatidylserine-omega 3 supplementation reduces attention deficit hyperactivity disorder (ADHD) symptoms in children [54]. This indicates that PS may prove beneficial in correcting disrupted neural function under various conditions. It also modulates several important enzymes and proteins, such as synapsin I, that maintain neural function [55]. Table V lists some of the studies depicting the role of PS in neurological conditions.
Tab. V.
Effect of phosphatidylserine on neurological conditions.
Neurological conditions | Subjects | Nutrients | Findings | References |
---|---|---|---|---|
Alzheimer’s disease | Aged patients with AD and dementia | Soy lecithin-derived phosphatidylserine plus phosphatidic acid | Improved cognition, mood, and memory | [58] |
Attention deficit hyperactivity disorder (ADHD) | Children with ADHD | Phosphatidylserine | Improved short-term auditory memory and ADHD symptoms | [59] |
Premenstrual syndrome (PMS) | 40 women age 18-45 years diagnosed with PMS | 400 mg PS + 400 mg PA per day or a matching placebo | Significant reduction in PMS symptoms | [60] |
Cognitive impairment | Elderly persons with impaired memory | 100 mg/day phosphatidylserine enriched with docosahexaenoic acid (PS-DHA) | May improve or maintain cognitive status | [61] |
Cognitive function improvement | Elderly persons with impaired memory without dementia | Phosphatidylserine enriched with docosahexaenoic acid (PS-DHA) | May improve cognitive performance | [62] |
Acute cognitive effects | Healthy young volunteers | Ginkgo biloba extract with soy-derived PS | Significantly improved memory task speed and improved secondary memory | [63] |
Cognition and cortical activity after mental stress | Healthy subjects doing cognitive tasks under induced stress in a test–re-test design | Phosphatidylserine supplementation | Continued supplementation significantly was connected with a more relaxed state compared to the controls | [64] |
Age-related cognitive function | 130 elderly persons with cognitive impairment | PS derived from soybean 300 mg/day | Safely improved cognitive function | [65] |
494 elderly persons with cognitive impairment | 300 mg/day PS supplements | Improved cognitive function in 6 months | [66] |
Phosphatidylcholine
Phosphatidylcholine (PC) is the major phospholipid component of cell membranes, lecithin, organ meats, nuts and spinach. Phosphatidylcholine supplements derived from egg yolk are well-absorbed in the gut and their levels can vary in different regions of the brain under different circumstances. For instance, PC and phosphatidylethanolamine levels increase in the whole brain of a stress-induced mouse model [56], while phosphatidylethanolamine and sphingomyelin levels decrease in the prefrontal cortex, and sphingomyelin in the hippocampus [47]. Likewise, an age-induced reduction in PC and phosphatidylethanolamine levels was detected by HPLC in the hippocampus and frontal cortex of elderly persons (89-92 years) [57].
EFFECTS OF GAMMA-AMINOBUTYRIC ACID ON BRAIN AND BEHAVIOUR
Gamma-aminobutyric acid (GABA) is a non-protein amino acid found in high concentrations in different parts of the brain [67]. Foods such as germinated brown rice, soybean, green tea, cabbage, yogurt, kimchi and pickles are excellent sources of GABA. GABA is the main inhibitory neurotransmitter in the human cerebral cortex [68]. As a food supplement it is used to alleviate anxiety and improve sleep quality. Several studies have reported that GABA crosses the blood-brain barrier, albeit in small amounts [69]. GABA is a known antihypertensive, anti-inflammatory, antidiabetic, antimicrobial, antiallergic, hepatoprotective, renal protective and intestine protective agent [70], and it demonstrated effects on several neurological disorders (Tab. VI).
Tab. VI.
GABA and prevention of neurological disorders.
Neurological conditions | Sources of GABA | Subjects | Effect on neurological conditions | Reference |
---|---|---|---|---|
Alzheimer’s disease | Naturally produced by cerebral cortex | Thirty-eight AD risk participants, 14 with normal cognitive function, 11 with cognitive decline, 13 with impaired cognitive function | In high-AD risk participants GABA levels were associated with the dorsomedial-dorsoanterolateral prefrontal cortex | [71] |
Menopausal depression, insomnia and autonomic disorder | GABA-enriched rice germ | Twenty menopausal patients | Improvement in sleep, somnipathy and depression | [72] |
Depression | GABA-rich Monascus-fermented product | Depression animal model | Prevented depression | [73] |
Sleep quality | GABA powder from lactic acid bacteria fermentation | 32 Japanese volunteers | Prevented sleep disorders | [74] |
Sleep latency and non-REM sleep | GABA (90.8%) and l-theanine (99.3%) | Pentobarbital-induced sleep in ICR mice | Decreased sleep latency and enhanced sleep duration | [75] |
Stress | GABA from natural fermentation with lactic acid bacteria | 8 stressed volunteers | Increased relaxation, reduced anxiety and raised immunity | [76] |
Cognitive function | GABA-enriched product fermented with kimchi-derived lactic acid bacteria | 50 mice | Improved long-term memory loss and increased neuronal proliferation | [77] |
GABA-enriched fermented Laminaria japonica product | 40 elderly persons | Prevented cognitive impairment in the elderly | [78] |
MELATONIN IN NEURODEGENERATION
Melatonin, a neurohormone secreted by the epiphysis cerebri and extra pineal structures, has several important functions (chronobiotic, normothermal, immune-modulating, antioxidant, oncostatic, cryoprotective and anxiolytic) in the body [79]. Melatonin affects the gastrointestinal tract, cardiovascular system, reproductive system and metabolism, and regulates body weight. Acting as a chronobiotic, melatonin modifies the phase and amplitude of biological rhythms. It acts as a cytoprotective molecule in neurodegenerative disorders and aging by reversing inflammatory damage. It also prevents neurodegeneration in experimental models of Alzheimer’s and Parkinson’s disease. Melatonin supplementation has been recommended for the treatment of insomnia [80]. Table VII lists the effects of melatonin supplementation on various neurological conditions.
Tab. VII.
Effects of melatonin supplementation on various neurological conditions.
Clinical condition | Melatonin dose | Findings | References |
---|---|---|---|
Parkinson’s disease | 0.25 and 1.25 mg/kg i.v. | Striking improvement in symptoms | [81] |
Amyotrophic lateral sclerosis | 60 mg/day oral for 13 months | Neuroprotective effects | [82] |
300 mg/day rectal for 2 years in 31 sporadic patients | Reduced oxidative damage | [83] | |
Muscular dystrophy | 70 mg/day for 9 months | Mitigated hyperoxidative state of erythrocytes | [84] |
Multiple sclerosis | 50-300 mg/day oral for 4 years | Improved overall symptoms of progressive MS with long-term use | [85] |
Migraine | 3 mg/day for 4 months | Lower duration, frequency, and intensity of pain | [86] |
OMEGA-3 FATTY ACIDS
Omega-3 fatty acids are essential for a variety of physiological functions involved in neuroinflammation, neurotransmission and neurogenesis and therefore play a major role in brain development, performance and aging. The importance of omega-3 fatty acids is indicated by the fact that a deficiency leads to many neurological conditions such as depression, ADHD, schizophrenia, bipolar disorder, dementia and autism (Tab. VIII). Eicosapentaenoic (EA) and docosahexaenoic (DA) acid modulate inflammatory processes and maintain mental health, while a deficiency results in mental disorders (Tab. VIII). They also directly affect neuronal membrane fluidity and receptor function. Although omega-3 supplementation and enriched foods have long been studied for their vital role in neurological homeostasis, randomized clinical trials investigating their therapeutic potential have yielded inconclusive results, limiting their use in psychiatry. High-quality clinical trials are urgently needed to evaluate the effectiveness of omega-3 fatty acids in inhibiting and treating NDs.
Tab. VIII.
Neurological implications of omega-3 fatty acids.
Neurological condition/function | Subjects | Study type | Supplements/ doses | Findings | Reference |
---|---|---|---|---|---|
Anxiety and inflammation | 68 medical students under low-stress such as exams | Placebo-controlled, double-blind 12-week RCT | n-3 (2.5 g/day, 2085 mg eicosapentaenoic acid and 348 mg docosahexaenoic acid) or placebo | 14% decrease in lipopolysaccharide-stimulated interleukin 6 production and 20% reduction in anxiety symptoms; lowered n-6:n-3 ratio and anxiety | [87] |
Dementia | 5386 patients without dementia | Prospective evaluation of incidence of dementia | Fatty-acid-rich fish | Fish intake decreased dementia | [88] |
Cognitive function | 867 elderly persons | Observational epidemiological | Oily fish containing long-chain PUFA | Fish consumption was positively associated with delayed unadjusted recall in CVLT | [89] |
Parkinson’s disease | 31 patients with major depression | Double-blind, placebo-controlled | Fish oil (containing omega-3 fatty acids) or mineral oil capsules for 3 months | Omega-3 enriched fish oil improved depression | [90] |
Alzheimer’s disease and vascular dementia | 49 controls, 25 AD and 15 VD | Cross-sectional | Excess intake of n-6 polyunsaturated fatty acids | AD and VD associated with higher intake of n-6 animal fats | [91] |
NEUROTROPIC B VITAMINS
Neurotropic B vitamins have crucial roles in the nervous system, not only as coenzymes. Their importance is indicated by the fact that their deficiency leads to various NDs such as depression, beriberi, Wernicke’s encephalopathy, seizures, subacute combined degeneration of the spinal cord and peripheral neuropathy [92, 93]. Synergistic interaction of vitamins B1, B6 and B12 has been reported to improve neuropathic pain, motor control and nociception (Tab. IX) [94].
Tab. IX.
Sources and neurological implications of vitamins B1, B6 and B12.
Vitamin | Sources | Coenzyme for | Deficiency symptoms | Implications in nervous system | Reference |
---|---|---|---|---|---|
B1 (thiamine) | Fish, beans, lentils, cereals, yogurt, sunflower seeds, cereals | Pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase, transketolase | Beriberi, polyneuritis | Energy supply to nerve cells for synthesis of nucleic acids, neurotransmitters, and myelin | [95, 96, 97] |
B6 (pyridoxine) | Salmon, tuna, beef liver, chicken, leafy greens, orange, banana, papaya, cantaloupe | Cystathionine-beta-synthase/lyase, serine-hydroxymethyl transferase, aromatic L-amino acid decarboxylase | Cognitive impairment, depression, premature aging of neurons | Metabolism of DNA/RNA, amino acids and neurotransmitters | [98] |
B12 (cobalamin) | Dairy products, fish, poultry, eggs, meat | Methionine synthase, methylmalonyl CoA mutase | Cognitive impairment, impaired neurotransmitter production, polyneuritis, subacute combined spinal cord sclerosis | Metabolism of nucleic acids, fatty acids, amino acids, neurotransmitters, myelin | [99] |
S-ADENOSYL METHIONINE (SAME)
S-adenosyl methionine (SAMe) is a major methyl donor that influences central nervous system function via cell transmethylation pathways, including but not limited to DNA methylation. It is a strong antidepressant with impacts in mouse models of amyotrophic lateral sclerosis, epilepsy and Alzheimer’s disease [100]. SAMe supplementation alters brain bioenergetics and is an effective treatment for depression (Tab. X) [101, 102].
Tab. X.
Neurological implications of S-adenosyl methionine (SAMe).
Neurological conditions | Study Design | Subjects | Dose | Findings | Reference |
---|---|---|---|---|---|
Abstinence from smoking | Three-arm, randomized, blind, placebo-controlled, dose-ranging clinical trial | 120 adults | Oral SAMe 800 or 1600 mg/day or matched placebo for 8 weeks | SAMe holds little promise for the treatment of tobacco dependence | [103] |
Parkinson’s disease | Open label clinical trial | 13 patients with depression | 800 to 3600 mg/day for 10 weeks | SAMe is a well-tolerated, safe and effective alternative to antidepressants | [104] |
Depression | Double blind randomised controlled trial | 49 patients with depression | 800 mg/day SAMe monotherapy versus placebo | Depression improved | [105] |
TRYPTOPHAN
Essential amino acid tryptophan (TRP) is involved in various physiological processes including immunity, neuronal function and gut homeostasis. Its metabolism in humans takes place via the kynurenine and serotonin pathways and produces niacin, serotonin and melatonin. In addition, to endogenous TRP, the gut microbiota also produces specific TRP metabolites that indirectly influence host physiology. An alteration in TRP metabolites results in neurological and psychiatric disorders. Tryptophan supplementation has been used to treat a number neuropsychological disorders in various clinical trials (Tab. XI) and has been found to improve serotonin and tryptophan deficiency, thus alleviating the severity of symptoms in depression, schizophrenia and bipolar disorder.
Tab. XI.
Clinical trials evaluating efficacy of tryptophan in neuropsychological disorders.
Neurological conditions | Study Design | Treatment | Findings | Reference |
---|---|---|---|---|
Depression | Human pilot clinical trial | Tryptophan | Replenished serotonin deficiency | [106] |
Schizophrenia | Open baseline-controlled trial | Tryptophan | Improved impaired serotonin synthesis | [107] |
Bipolar disorder | Clinical trial | L-tryptophan | Alleviated tryptophan deficiency | [108] |
MAGNESIUM
Magnesium is an important mineral for homeostasis in the human body. It plays an essential role in neuroprotection, neuromuscular conduction and nerve transmission. It is a mineral of intense interest due to its capacity to protect the nervous system against ecotoxicity, thus improving many neurological disorders. Table XII shows some selective studies of magnesium in NDs.
Tab. XII.
Neurological implications of magnesium.
Neurological conditions | Study Design/type | Subjects | Treatment/ supplementation/ assessment | Findings | Reference |
---|---|---|---|---|---|
Risk of dementia | Prospective cohort Hisayama Study, Japan | 1081 Japanese without dementia, age > 60 years, 17-year follow-up | Dietary intake of potassium, calcium, magnesium | Higher self-reported dietary potassium, calcium and magnesium intake reduces risk of dementia | [109] |
Alzheimer’s disease | Comprehensive geriatric assessment | 101 geriatric patients with slight to moderate cognitive impairment | Assessment of Mg levels in blood samples | Mg ion levels were directly related to cognitive function | [110] |
Parkinson’s disease | Case control study | 249 patients with PD for < 6 years and 368 controls | Dietary intake | Higher intake of magnesium, iron and zinc associated with lower risk of PD | [111] |
Cerebral ischemia | Intravenous magnesium efficacy in stroke (IMAGES) trial | 2589 | A bolus dose of 16 mmol of MgSO4 was infused over 15 min and then a maintenance dose of 65 mmol MgSO4 was given over 24 h | Highly beneficial in early-treated patients | [112] |
POLYPHENOLS
Polyphenols are important nutrients abundant in spices and foods. They have antioxidant, anti-inflammatory and senolytic activities; they inhibit oxytosis, modulate the gut microbiome and promote protein aggregation and stability. They also maintain GSH levels and neurotrophic signalling pathways [113]. They show promise for preventing neurodegenerative diseases such as dementia, PD, HD, ALS, stroke, TBI, diabetes, cardiovascular diseases, liver disease and cancers. In addition, polyphenols control symptoms of depression. For instance, the antioxidant potential of polyphenols could possibly improve depression symptoms in women [114]. However, the effect of polyphenols in disease prevention and treatment depends on adequate dietary consumption. Fresh fruit and vegetables contain plenty of polyphenols that offer a variety of neurological benefits (Tab. XII). Polyphenol supplements, such as Pycnogenol® (a procyanidin) obtained from French maritime pine bark by Horphag Research (Geneva, Switzerland), have shown promising antioxidant and anti-inflammatory properties in various in vitro, animal and/or human models [115], besides improving endothelial function and showing beneficial effects in ADHD [116]. Another important commercially available polyphenol is silymarin, extracted from milk thistle and sold with various brand names. It is commonly known as flavonolignans and is a mixture of eight stereoisomers: taxofolin, silybin A and B, isosilybin A and B, silychristin, isosilychristin and silydianin [117].
Silymarin shows neuroprotective mechanisms in AD, PD and cerebral ischemia including mediation of antioxidant mechanisms, regulation of kinases in cell signalling pathways, anti-inflammatory properties, neurotropic effects, modulation of neurotransmitters and inhibition of apoptosis [118, 119]. Silymarin also controls production of amyloid-β by inhibiting β-amyloid precursor protein and cholinesterase activity, thus inhibiting the onset of AD [120]. Its low cost, bioavailability and safety make silymarin a natural drug of choice for neuroprotection and hepatoprotection [119, 120].
Ayurvedic herbs in the treatment of neurodegenerative diseases
Ayurvedic medicine has been practised in the Asian subcontinent since ancient times. Many herbs and medicinal plants have been explored for their antioxidant, anti-inflammatory, antidiabetic, anticancer and cytoprotective properties. Medicinal plants such as Withania somnifera (ashwagandha), Baccopa monnieri, Acorus calamus and Hypericum perforatum have been shown to prevent or alleviate neurological diseases and symptoms (Tab. XIV).
Tab. XIV.
Neuroprotective properties and therapeutic potential of selected medicinal plants.
Medicinal plants | Active ingredients | Neuroprotective properties | Therapeutic potential | Reference |
---|---|---|---|---|
Bacopa monnieri (L.) Wettest (folk name: brahmi) | Bacopasides III–V, bacosides A and B, bacosaponins A, B and C | Antioxidant, antistress, anti-inflammatory, anti-microbial and smooth muscle relaxant. Improves memory | Neuroprotection in AD and bipolar disorder, improves intelligence and memory | [130, 133, 134] |
Withania somnifera (L.) Dunal (folk name: ashwaganda) | Ashwagandhine, withanolides, withasomniferin, withasomniferols and withanone | Memory enhancer and anti-stress agent with effects on locomotor function and neural growth | Inhibits oxidative stress, improves cholinergic function and mitochondrial respiration in rotenone-induced Parkinsonism in Drosophila melanogaster | [131] |
Acorus calamus (folk name: sweet flag, sway or muskrat root) | 145 compounds α-asarone, β-asarone, eugenol, isoeugenol, 44 sesquiterpenes including lactones, monoterpenes (C-10), triterpenoid saponins | Antioxidant, anti-depressant, anti-inflammatory, anticonvulsant, neuroprotective, antianxiety, cytoprotective, immunomodulatory | Neuroprotection and anti-inflammatory agent in AD and PD | [132, 135] |
Hypericum perforatum (Folk name: St John’s wort) | Quercetin, hyperoside, quercitrin, rutin, hypericin, kaempferol, hyperforin | Antidepressive, antioxidant, neuroprotective | Restoration and improvement of microglial viability, inhibits amyloid-β toxicity in AD and brain malondialdehyde in PD | [47] |
Bacopa monnieri
Bacopa monnieri is a traditional Indian ayurvedic medicinal plant belonging to the family Scrophulariaceae. This memory enhancer, known as Brahmi, has been used traditionally for more than 3000 years to treat various neurological disorders, to enhance digestion and to improve learning, cognitive function and concentration. It helps restore cognitive deficit and enhances mental and brain function. This nootropic plant promotes repair of damaged neurons, neuronal synthesis and synaptic activity. Recent studies show that it contains surplus bioactive phytochemical compounds with synergistic properties that are useful in the management of ND [130].
Withania somnifera
Withania somnifera or ashwagandha is another traditional Indian medicinal plant that promotes long life, youthful vigour and good intellectual powers. It is used traditionally in the treatment of neurodegenerative diseases, general frailty, nervous exhaustion and insomnia. It has anti-inflammatory, anti-tumour, antioxidant, immunomodulatory and anti-neuropsychiatric effects [131].
Acorus calamus
Acorus calamus or vacha is a traditional Indian ayurvedic medicinal plant. Its rhizomes are used to treat insomnia, melancholy, memory loss, hysteria, depression and mental disorders. Almost all parts of the plant have proven beneficial in the treatment of neurological, gastrointestinal, kidney, respiratory, liver, and metabolic disorders. Its action is anticonvulsant, anti-depressant, anti-hypersensitive, anti-inflammatory, cardioprotective, immunomodulatory and anti-obesity [132].
Hypericum perforatum
Hypericum perforatum or St. John’s wort is a perennial plant. It is used in traditional medicine to treat external and internal disorders such as minor burns, anxiety and mild to moderate depression. It is also a herbal remedy for neurological disorders such as mental aliments, hypersensitivity, neuralgia, spinal convulsion, hydrophobia, spastic paralysis, spinal irritation, coxalgia and menopausal neurosis [47].
Conclusion
Oxidative stress and neuroinflammation are key factors in the onset and progression of neurodegenerative diseases. A diet rich in biologically active compounds with antioxidative and anti-inflammatory properties affords significant neuroprotection. Many recent studies have attempted to evaluate and recommend the Mediterranean diet and its ingredients with neuroprotective, oxidative stress mitigating and anti-inflammatory properties that impede the progression, delay the onset and reduce the severity of neurodegeneration in neurological disorders such as AD, PD, HD, MS, ALS and natural age-related brain aging. Several natural compounds, minerals and medicinal plants have been tested in clinical trials and animal studies and some, such as PLs, GABA, NAC, omega-3 fatty acids, magnesium, curcumin, resveratrol, Hypericum perforatum, Acorous calamus and Bacopa monnieri, have proven beneficial, safe and economical in the treatment of NDs. However, their effects are dose-dependent and must be administered in a precise manner. These potentially beneficial dietary components need to be evaluated in large clinical trials to assess their wider application across patients of different ethnic origin.
Acknowledgements
This research was funded by the Provincia Autonoma di Bolzano in the framework of LP 15/2020 (dgp 3174/2021).
Conflicts of interest statement
Authors declare no conflict of interest.
Author's contributions
MB: study conception, editing and critical revision of the manuscript; KD, MCM, Paola C, PM, Pietro C: literature search, editing and critical revision of the manuscript. All authors have read and approved the final manuscript.
Figures and tables
Tab. XIII.
Dietary sources and neurological benefits of polyphenols.
Class of polyphenols | Biologically active compound | Dietary source | Neurological benefits | References |
---|---|---|---|---|
Non flavonoids | Curcumin | Turmeric | Significant reduction in severity of depression and improved cognitive function in elderly AD patients | [121, 122, 123, 124] |
Resveratrol | Grapes | Improved cognitive function, reduced oxidative stress and neuroinflammation, and neuroprotection in AD patients | [125, 126] | |
Anthocyanins | Cyanidin petunidin | Berries strawberries tea | Improved cognitive function and reduced risk of dementia | [127] |
Flavones | Apigenin kaempferol myricetin quercetin | Apple skin, broccoli, fruit peel, lettuce, olives and onions | Quercetin reduces risk of AD and regulates microglial activity, neuroinflammation, oxidative stress and neural injury | [128, 129] |
Flavonones | Fisetin hesperitin | Citrus fruit and peel | Fisetin slows loss of cognitive function and maintains brain health in dementia models | [113] |
References
- [1].Bianchi VE, Herrera PF, Laura R. Effect of nutrition on neurodegenerative diseases. A systematic review. Nutr Neurosci 2021;24:810-34. https://doi.org/10.1080/1028415X.2019.1681088 10.1080/1028415X.2019.1681088 [DOI] [PubMed] [Google Scholar]
- [2].Caplliure-Llopis J, Peralta-Chamba T, Carrera-Juliá S, Cuerda-Ballester M, Drehmer-Rieger E, López-Rodriguez MM, de la Rubia Ortí JE. Therapeutic alternative of the ketogenic Mediterranean diet to improve mitochondrial activity in Amyotrophic Lateral Sclerosis (ALS): A Comprehensive Review. Food Sci Nutr 2019;8:23-35. https://doi.org/10.1002/fsn3.1324 10.1002/fsn3.1324 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [3].Esposito E, Rotilio D, Di Matteo V, Di Giulio C, Cacchio M, Algeri S. A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes. Neurobiol Aging 2002;23:719-35. https://doi.org/10.1016/s0197-4580(02)00078-7 10.1016/s0197-4580(02)00078-7 [DOI] [PubMed] [Google Scholar]
- [4].Lardenoije R, van den Hove DLA, Havermans M, van Casteren A, Le KX, Palmour R, Lemere CA, Rutten BPF. Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer’s disease. Mol Cell Neurosci 2018;86:1-15. https://doi.org/10.1016/j.mcn.2017.11.002 10.1016/j.mcn.2017.11.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [5].Chiurazzi P, Kiani AK, Miertus J, Paolacci S, Barati S, Manara E, Stuppia L, Gurrieri F, Bertelli M. Genetic analysis of intellectual disability and autism. Acta Biomed 2020;91:e2020003. https://doi.org/10.23750/abm.v91i13-S.10684 10.23750/abm.v91i13-S.10684 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [6].Allison J, Kaliszewska A, Uceda S, Reiriz M, Arias N. Targeting DNA Methylation in the Adult Brain through Diet. Nutrients 2021;13:3979. https://doi.org/10.3390/nu13113979 10.3390/nu13113979 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [7].Berti V, Walters M, Sterling J, Quinn CG, Logue M, Andrews R, Matthews DC, Osorio RS, Pupi A, Vallabhajosula S, Isaacson RS, de Leon MJ, Mosconi L. Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology 2018;90:e1789-e1798. https://doi.org/10.1212/WNL.0000000000005527 10.1212/WNL.0000000000005527 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol 2009;66:216-25. https://doi.org/10.1001/archneurol.2008.536 10.1001/archneurol.2008.536 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [9].Anastasiou CA, Yannakoulia M, Kosmidis MH, Dardiotis E, Hadjigeorgiou GM, Sakka P, Arampatzi X, Bougea A, Labropoulos I, Scarmeas N. Mediterranean diet and cognitive health: Initial results from the Hellenic Longitudinal Investigation of Ageing and Diet. PLoS One 2017;12:e0182048. https://doi.org/10.1371/journal.pone.0182048 10.1371/journal.pone.0182048 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [10].Mosconi L, Murray J, Tsui WH, Li Y, Davies M, Williams S, Pirraglia E, Spector N, Osorio RS, Glodzik L, McHugh P, de Leon MJ. Mediterranean Diet and Magnetic Resonance Imaging-Assessed Brain Atrophy in Cognitively Normal Individuals at Risk for Alzheimer’s Disease. J Prev Alzheimers Dis 2014;1:23-32. [PMC free article] [PubMed] [Google Scholar]
- [11].Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson IHuntington Study Group PHAROS Investigators. Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol 2013;70:1382-8. https://doi.org/10.1001/jamaneurol.2013.3487 10.1001/jamaneurol.2013.3487 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [12].Maraki MI, Yannakoulia M, Stamelou M, Stefanis L, Xiromerisiou G, Kosmidis MH, Dardiotis E, Hadjigeorgiou GM, Sakka P, Anastasiou CA, Simopoulou E, Scarmeas N. Mediterranean diet adherence is related to reduced probability of prodromal Parkinson’s disease. Mov Disord 2019;34:48-57. https://doi.org/10.1002/mds.27489 10.1002/mds.27489 [DOI] [PubMed] [Google Scholar]
- [13].Nieves JW, Gennings C, Factor-Litvak P, Hupf J, Singleton J, Sharf V, Oskarsson B, Fernandes Filho JA, Sorenson EJ, D’Amico E, Goetz R, Mitsumoto HAmyotrophic Lateral Sclerosis Multicenter Cohort Study of Oxidative Stress (ALS COSMOS) Study Group. Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis. JAMA Neurol 2016;73:1425-32. https://doi.org/10.1001/jamaneurol.2016.3401 10.1001/jamaneurol.2016.3401 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [14].Zhang WT, Zhang GX, Zhao RZ, Gao SS, Zhao G., Izquierdo G. Eating habits of patients with multiple sclerosis in three different countries: China, Spain and Cuba. Neurology Perspectives 2021;1:170-7. https://doi.org/10.1016/j.neurop.2021.07.001 10.1016/j.neurop.2021.07.001 [DOI] [Google Scholar]
- [15].Kouka P, Priftis A, Stagos D, Angelis A, Stathopoulos P, Xinos N, Skaltsounis AL, Mamoulakis C, Tsatsakis AM, Spandidos DA, Kouretas D. Assessment of the antioxidant activity of an olive oil total polyphenolic fraction and hydroxytyrosol from a Greek Olea europea variety in endothelial cells and myoblasts. Int J Mol Med 2017;40:703-12. https://doi.org/10.3892/ijmm.2017.3078 10.3892/ijmm.2017.3078 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [16].Kiani AK, Miggiano G, Aquilanti B, Velluti V, Matera G, Gagliardi L, Bertelli M. Food supplements based on palmitoylethanolamide plus hydroxytyrosol from olive tree or Bacopa monnieri extracts for neurological diseases. Acta Biomed 2020;91:2020007. https://doi.org/10.23750/abm.v91i13-S.10582 10.23750/abm.v91i13-S.10582 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [17].Kalaiselvan I, Samuthirapandi M, Govindaraju A, Sheeja Malar D, Kasi PD. Olive oil and its phenolic compounds (hydroxytyrosol and tyrosol) ameliorated TCDD-induced heptotoxicity in rats via inhibition of oxidative stress and apoptosis. Pharm Biol 2016;54:338-46. https://doi.org/10.3109/13880209.2015.1042980 10.3109/13880209.2015.1042980 [DOI] [PubMed] [Google Scholar]
- [18].Grossi C, Rigacci S, Ambrosini S, Ed Dami T, Luccarini I, Traini C, Failli P, Berti A, Casamenti F, Stefani M. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aß plaque pathology. PLoS One 2013;8:e71702. https://doi.org/10.1371/journal.pone.0071702 10.1371/journal.pone.0071702 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [19].Zoccolella S, Beghi E, Palagano G, Fraddosio A, Guerra V, Samarelli V, Lepore V, Simone IL, Lamberti P, Serlenga L, Logroscino G. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2008;79:33-7. https://doi.org/10.1136/jnnp.2007.118018 10.1136/jnnp.2007.118018 [DOI] [PubMed] [Google Scholar]
- [20].Mancuso C, Santangelo R. Ferulic acid: pharmacological and toxicological aspects. Food Chem Toxicol 2014;65:185-95. https://doi.org/10.1016/j.fct.2013.12.024 10.1016/j.fct.2013.12.024 [DOI] [PubMed] [Google Scholar]
- [21].Debbabi M, Zarrouk A, Bezine M, Meddeb W, Nury T, Badreddine A, Karym EM, Sghaier R, Bretillon L, Guyot S, Samadi M, Cherkaoui-Malki M, Nasser B, Mejri M, Ben-Hammou S, Hammami M, Lizard G. Comparison of the effects of major fatty acids present in the Mediterranean diet (oleic acid, docosahexaenoic acid) and in hydrogenated oils (elaidic acid) on 7-ketocholesterol-induced oxiapoptophagy in microglial BV-2 cells. Chem Phys Lipids 2017;207:151-70. https://doi.org/10.1016/j.chemphyslip.2017.04.002 10.1016/j.chemphyslip.2017.04.002 [DOI] [PubMed] [Google Scholar]
- [22].Rogers PJ. A healthy body, a healthy mind: long-term impact of diet on mood and cognitive function. Proc Nutr Soc 2001;60:135-43. https://doi.org/10.1079/pns200061 10.1079/pns200061 [DOI] [PubMed] [Google Scholar]
- [23].Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Marangell LB. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.Arch Gen Psychiatry 1999;56:407-12. https://doi.org/10.1001/archpsyc.56.5.407 10.1001/archpsyc.56.5.407 [DOI] [PubMed] [Google Scholar]
- [24].Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D, Lönnqvist J. Food and nutrient intake in relation to mental wellbeing. Nutr J 2004;3:14. https://doi.org/10.1186/1475-2891-3-14 10.1186/1475-2891-3-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [25].Parletta N, Zarnowiecki D, Cho J, Wilson A, Bogomolova S, Villani A, Itsiopoulos C, Niyonsenga T, Blunden S, Meyer B, Segal L, Baune BT, O’Dea K. A Mediterranean-style dietary intervention supplemented with fish oil improves diet quality and mental health in people with depression: A randomized controlled trial (HELFIMED). Nutr Neurosci 2019;22:474-87. https://doi.org/10.1080/1028415X.2017.1411320 10.1080/1028415X.2017.1411320 [DOI] [PubMed] [Google Scholar]
- [26].Jacka FN, O’Neil A, Opie R, Itsiopoulos C, Cotton S, Mohebbi M, Castle D, Dash S, Mihalopoulos C, Chatterton ML, Brazionis L, Dean OM, Hodge AM, Berk M. A randomised controlled trial of dietary improvement for adults with major depression (the ‘SMILES’ trial). BMC Med 2017;15:23. https://doi.org/10.1186/s12916-017-0791-y 10.1186/s12916-017-0791-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- [27].Bayes J, Schloss J, Sibbritt D. Effects of Polyphenols in a Mediterranean Diet on Symptoms of Depression: A Systematic Literature Review. Adv Nutr 2020;11:602-15. https://doi.org/10.1093/advances/nmz117 10.1093/advances/nmz117 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [28].García-Toro M, Vicens-Pons E, Gili M, Roca M, Serrano-Ripoll MJ, Vives M, Leiva A, Yáñez AM, Bennasar-Veny M, Oliván-Blázquez B. Obesity, metabolic syndrome and Mediterranean diet: Impact on depression outcome. J Affect Disord 2016;194:105-8. https://doi.org/10.1016/j.jad.2015.12.064 10.1016/j.jad.2015.12.064 [DOI] [PubMed] [Google Scholar]
- [29].Vicinanza R, Bersani FS, D’Ottavio E, Murphy M, Bernardini S, Crisciotti F, Frizza A, Mazza V, Biondi M, Troisi G, Cacciafesta M. Adherence to Mediterranean diet moderates the association between multimorbidity and depressive symptoms in older adults. Arch Gerontol Geriatr 2020;88:104022. https://doi.org/10.1016/j.archger.2020.104022 10.1016/j.archger.2020.104022 [DOI] [PubMed] [Google Scholar]
- [30].Sánchez-Villegas A, Cabrera-Suárez B, Molero P, González-Pinto A, Chiclana-Actis C, Cabrera C, Lahortiga-Ramos F, Florido-Rodríguez M, Vega-Pérez P, Vega-Pérez R, Pla J, Calviño-Cabada MJ, Ortuño F, Navarro S, Almeida Y, Hernández-Fleta JL. Preventing the recurrence of depression with a Mediterranean diet supplemented with extra-virgin olive oil. The PREDI-DEP trial: study protocol. BMC Psychiatry 2019;19:63. https://doi.org/10.1186/s12888-019-2036-4 10.1186/s12888-019-2036-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [31].Jacka FN, Pasco JA, Mykletun A, Williams LJ, Nicholson GC, Kotowicz MA, Berk M. Diet quality in bipolar disorder in a population-based sample of women. J Affect Disord 2011;129:332-7. https://doi.org/10.1016/j.jad.2010.09.004 10.1016/j.jad.2010.09.004 [DOI] [PubMed] [Google Scholar]
- [32].Gesch CB, Hammond SM, Hampson SE, Eves A, Crowder MJ. Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial. Br J Psychiatry 2002;181:22-8. https://doi.org/10.1192/bjp.181.1.22 10.1192/bjp.181.1.22 [DOI] [PubMed] [Google Scholar]
- [33].Neumeister A, Turner EH, Matthews JR, Postolache TT, Barnett RL, Rauh M, Vetticad RG, Kasper S, Rosenthal NE. Effects of tryptophan depletion vs catecholamine depletion in patients with seasonal affective disorder in remission with light therapy. Arch Gen Psychiatry 1998;55:524-30. https://doi.org/10.1001/archpsyc.55.6.524 10.1001/archpsyc.55.6.524 [DOI] [PubMed] [Google Scholar]
- [34].Reynolds EH. Folic acid, ageing, depression, and dementia. BMJ 2002;324:1512-5. https://doi.org/10.1136/bmj.324.7352.1512 10.1136/bmj.324.7352.1512 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [35].Botez MI, Fontaine F, Botez T, Bachevalier J. Folate-responsive neurological and mental disorders: report of 16 cases. Neuropsychological correlates of computerized transaxial tomography and radionuclide cisternography in folic acid deficiencies. Eur Neurol 1977;16:230-46. https://doi.org/10.1159/000114904 10.1159/000114904 [DOI] [PubMed] [Google Scholar]
- [36].Goodwin JS, Goodwin JM, Garry PJ. Association between nutritional status and cognitive functioning in a healthy elderly population. JAMA 1983;249:2917-21. [PubMed] [Google Scholar]
- [37].Dekhuijzen PN. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004;23:629-36. https://doi.org/10.1183/09031936.04.00016804 10.1183/09031936.04.00016804 [DOI] [PubMed] [Google Scholar]
- [38].Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav 2014;4:108-22. https://doi.org/10.1002/brb3.208 10.1002/brb3.208 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [39].Arakawa M, Ito Y. N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum 2007;6:308-14. https://doi.org/10.1080/14734220601142878 10.1080/14734220601142878 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [40].Stanislaus R, Gilg AG, Singh AK, Singh I. N-acetyl-L-cysteine ameliorates the inflammatory disease process in experimental autoimmune encephalomyelitis in Lewis rats. J Autoimmune Dis 2005;2:4. https://doi.org/10.1186/1740-2557-2-4 10.1186/1740-2557-2-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [41].Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 1995;52:559-64. https://doi.org/10.1001/archneur.1995.00540300031009 10.1001/archneur.1995.00540300031009 [DOI] [PubMed] [Google Scholar]
- [42].Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 1990;55:2142-5. https://doi.org/10.1111/j.1471-4159.1990.tb05809.x 10.1111/j.1471-4159.1990.tb05809.x [DOI] [PubMed] [Google Scholar]
- [43].Tchantchou F, Graves M, Rogers E, Ortiz D, Shea TB. N-acteyl cysteine alleviates oxidative damage to central nervous system of ApoE-deficient mice following folate and vitamin E-deficiency. J Alzheimers Dis 2005;7:135-8. https://doi.org/10.3233/jad-2005-7206 10.3233/jad-2005-7206 [DOI] [PubMed] [Google Scholar]
- [44].Dawson TM, Dawson VL. Protection of the brain from ischemia. Cerebrovasc Dis 1997;7:349-52. [Google Scholar]
- [45].Khrameeva E, Kurochkin I, Bozek K, Giavalisco P, Khaitovich P. Lipidome Evolution in Mammalian Tissues. Mol Biol Evol 2018;35:1947-57. https://doi.org/10.1093/molbev/msy097 10.1093/molbev/msy097 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [46].Choi J, Yin T, Shinozaki K, Lampe JW, Stevens JF, Becker LB, Kim J. Comprehensive analysis of phospholipids in the brain, heart, kidney, and liver: brain phospholipids are least enriched with polyunsaturated fatty acids. Mol Cell Biochem 2018;442:187-201. https://doi.org/10.1007/s11010-017-3203-x 10.1007/s11010-017-3203-x [DOI] [PMC free article] [PubMed] [Google Scholar]
- [47].Oliveira TG, Chan RB, Bravo FV, Miranda A, Silva RR, Zhou B, Marques F, Pinto V, Cerqueira JJ, Di Paolo G, Sousa N. The impact of chronic stress on the rat brain lipidome. Mol Psychiatry 2016;21:80-8. https://doi.org/10.1038/mp.2015 10.1038/mp.2015 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [48].Schverer M, O’Mahony SM, O’Riordan KJ, Donoso F, Roy BL, Stanton C, Dinan TG, Schellekens H, Cryan JF. Dietary phospholipids: Role in cognitive processes across the lifespan. Neurosci Biobehav Rev 2020;111:183-93. https://doi.org/10.1016/j.neubiorev.2020.01.012 10.1016/j.neubiorev.2020.01.012 [DOI] [PubMed] [Google Scholar]
- [49].Liu H, Radlowski EC, Conrad MS, Li Y, Dilger RN, Johnson RW. Early supplementation of phospholipids and gangliosides affects brain and cognitive development in neonatal piglets. J Nutr 2014;144:1903-9. https://doi.org/10.3945/jn.114.199828 10.3945/jn.114.199828 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [50].Hanin I, Ansell GB. Lecithin. Technological, biological, and therapeutic aspects. Boston: Spinger; 1987. https://doi.org/10.1007/978-1-4757-1933-8 10.1007/978-1-4757-1933-8 [DOI] [Google Scholar]
- [51].Mark A, McDaniel Steven F, Maier Gilles O. Einstein. “Brain-specific” nutrients: a memory cure? Nutrition 2003;19:957-75. https://doi.org/10.1016/s0899-9007(03)00024-8 10.1016/s0899-9007(03)00024-8 [DOI] [PubMed] [Google Scholar]
- [52].Crook TH, Tinklenberg J, Yesavage J, Petrie W, Nunzi MG, Massari DC. Effects of phosphatidylserine in age-associated memory impairment. Neurology 1991;41:644-9. https://doi.org/10.1212/wnl.41.5.644 10.1212/wnl.41.5.644 [DOI] [PubMed] [Google Scholar]
- [53].Hellhammer J, Vogt D, Franz N, Freitas U, Rutenberg D. A soy-based phosphatidylserine/ phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects: a randomized, placebo-controlled study. Lipids Health Dis 2014;13:121. https://doi.org/10.1186/1476-511X-13-121 10.1186/1476-511X-13-121 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [54].Manor I, Magen A, Keidar D, Rosen S, Tasker H, Cohen T, Richter Y, Zaaroor-Regev D, Manor Y, Weizman A. The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children: a double-blind placebo-controlled trial, followed by an open-label extension. Eur Psychiatry 2012;27:335-42. https://doi.org/10.1016/j.eurpsy.2011.05.004 10.1016/j.eurpsy.2011.05.004 [DOI] [PubMed] [Google Scholar]
- [55].Murray J, Cuccia L, Ianoul A, Cheetham JJ, Johnston LJ. Imaging the selective binding of synapsin to anionic membrane domains. Chembiochem 2004;5:1489-94. https://doi.org/10.1002/cbic.200400097 10.1002/cbic.200400097 [DOI] [PubMed] [Google Scholar]
- [56].Faria R, Santana MM, Aveleira CA, Simões C, Maciel E, Melo T, Santinha D, Oliveira MM, Peixoto F, Domingues P, Cavadas C, Domingues MR. Alterations in phospholipidomic profile in the brain of mouse model of depression induced by chronic unpredictable stress. Neuroscience 2014;273:1-11. https://doi.org/10.1016/j.neuroscience.2014.04.042 10.1016/j.neuroscience.2014.04.042 [DOI] [PubMed] [Google Scholar]
- [57].Söderberg M, Edlund C, Kristensson K, Dallner G. Lipid compositions of different regions of the human brain during aging. J Neurochem 1990;54:415-23. https://doi.org/10.1111/j.1471-4159.1990.tb01889.x 10.1111/j.1471-4159.1990.tb01889.x [DOI] [PubMed] [Google Scholar]
- [58].Moré MI, Freitas U, Rutenberg D. Positive effects of soy lecithin-derived phosphatidylserine plus phosphatidic acid on memory, cognition, daily functioning, and mood in elderly patients with Alzheimer’s disease and dementia. Adv Ther 2014;31:1247-62. https://doi.org/10.1007/s12325-014-0165-1 10.1007/s12325-014-0165-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [59].Hirayama S, Terasawa K, Rabeler R, Hirayama T, Inoue T, Tatsumi Y, Purpura M, Jäger R. The effect of phosphatidylserine administration on memory and symptoms of attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled clinical trial. J Hum Nutr Diet 2014;27:284-91. https://doi.org/10.1111/jhn.12090 10.1111/jhn.12090 [DOI] [PubMed] [Google Scholar]
- [60].Vakhapova V, Cohen T, Richter Y, Herzog Y, Kam Y, Korczyn AD. Phosphatidylserine containing omega-3 Fatty acids may improve memory abilities in nondemented elderly individuals with memory complaints: results from an open-label extension study. Dement Geriatr Cogn Disord 2014;38:39-45. https://doi.org/10.1159/000357793 10.1159/000357793 [DOI] [PubMed] [Google Scholar]
- [61].Vakhapova V, Cohen T, Richter Y, Herzog Y, Korczyn AD. Phosphatidylserine containing omega-3 fatty acids may improve memory abilities in non-demented elderly with memory complaints: a double-blind placebo-controlled trial. Dement Geriatr Cogn Disord 2010;29:467-74. https://doi.org/10.1159/000310330 10.1159/000310330 [DOI] [PubMed] [Google Scholar]
- [62].Kennedy DO, Haskell CF, Mauri PL, Scholey AB. Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine. Hum Psychopharmacol 2007;22:199-210. https://doi.org/10.1002/hup.837 10.1002/hup.837 [DOI] [PubMed] [Google Scholar]
- [63].Baumeister J, Barthel T, Geiss KR, Weiss M. Influence of phosphatidylserine on cognitive performance and cortical activity after induced stress. Nutr Neurosci 2008;11:103-10. https://doi.org/10.1179/147683008X301478 10.1179/147683008X301478 [DOI] [PubMed] [Google Scholar]
- [64].Jorissen BL, Brouns F, Van Boxtel MP, Riedel WJ. Safety of soy-derived phosphatidylserine in elderly people. Nutr Neurosci 2002;5:337-43. https://doi.org/10.1080/1028415021000033802 10.1080/1028415021000033802 [DOI] [PubMed] [Google Scholar]
- [65].Cenacchi T, Bertoldin T, Farina C, Fiori MG, Crepaldi G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on efficacy of phosphatidylserine administration. Aging (Milano) 1993;5:123-33. https://doi.org/10.1007/BF03324139 10.1007/BF03324139 [DOI] [PubMed] [Google Scholar]
- [66].Olsen RW, DeLorey TM. GABA and Glycine. In: Siegel GJ, Agranoff BW, Albers RW, Fisher S K, Uhler MD, eds. Basic neurochemistry: molecular, cellular and medical aspects. Sixth edition. Philadelphia: Lippincott-Raven; 1999. [Google Scholar]
- [67].Nuss P. Anxiety disorders and GABA neurotransmission: a disturbance of modulation. Neuropsychiatr Dis Treat 2015;11:165-75. https://doi.org/10.2147/NDT.S58841 10.2147/NDT.S58841 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [68].Byun JI, Shin YY, Chung SE, Shin WC. Safety and Efficacy of Gamma-Aminobutyric Acid from Fermented Rice Germ in Patients with Insomnia Symptoms: A Randomized, Double-Blind Trial. J Clin Neurol 2018;14:291-5. https://doi.org/10.3988/jcn.2018.14.3.291 10.3988/jcn.2018.14.3.291 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [69].Ngo DH, Vo TS. An Updated Review on Pharmaceutical Properties of Gamma-Aminobutyric Acid MoleculesM 2019;24:2678. https://doi.org/10.3390/molecules24152678 10.3390/molecules24152678 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [70].Murari G, Liang DR, Ali A, Chan F, Mulder-Heijstra M, Verhoeff NPLG, Herrmann N, Chen JJ, Mah L. Prefrontal GABA Levels Correlate with Memory in Older Adults at High Risk for Alzheimer’s Disease. Cereb Cortex Commun 2020;1:tgaa022. https://doi.org/10.1093/texcom/tgaa022 10.1093/texcom/tgaa022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [71].Okada T, Sugishita T, Murakami T, Murai H, Saikusa T, Horino T, Onoda A, Kajimoto O, Takahashi R, Takahashi T. Effect of the Defatted Rice Germ Enriched with GABA for Sleeplessness, Depression, Autonomic Disorder by Oral Administration. Nippon Shokuhin Kagaku Kogaku Kaishi 2000;47:596-603. https://doi.org/10.3136/nskkk.47.596 10.3136/nskkk.47.596 [DOI] [Google Scholar]
- [72].Chuang CY, Shi YC, You HP, Lo YH, Pan TM. Antidepressant effect of GABA-rich monascus-fermented product on forced swimming rat model. J Agric Food Chem 2011;59:3027-34. https://doi.org/10.1021/jf104239m 10.1021/jf104239m [DOI] [PubMed] [Google Scholar]
- [73].Yamatsu A, Yamashita Y, Pandharipande T, Maru I, Kim M. Effect of oral γ-aminobutyric acid (GABA) administration on sleep and its absorption in humans. Food Sci Biotechnol 2016;25:547-51. https://doi.org/10.1007/s10068-016-0076-9 10.1007/s10068-016-0076-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [74].Kim S, Jo K, Hong KB, Han SH, Suh HJ. GABA and l-theanine mixture decreases sleep latency and improves NREM sleep. Pharm Biol 2019;57:65-73. https://doi.org/10.1080/13880209.2018.1557698 10.1080/13880209.2018.1557698 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [75].Abdou AM, Higashiguchi S, Horie K, Kim M, Hatta H, Yokogoshi H. Relaxation and immunity enhancement effects of gamma-aminobutyric acid (GABA) administration in humans. Biofactors 2006;26:201-8. https://doi.org/10.1002/biof.5520260305 10.1002/biof.5520260305 [DOI] [PubMed] [Google Scholar]
- [76].Seo YC, Choi WY, Kim JS, Lee CG, Ahn JH, Cho HY, Lee SH, Cho JS, Joo SJ, Lee HY. Enhancement of the Cognitive Effects of γ-Aminobutyric Acid from Monosodium Glutamate Fermentation by Lactobacillus sakei B2-16. Food Biotechnol 2012;26:29-44. https://doi.org/10.1080/08905436.2011.645937 10.1080/08905436.2011.645937 [DOI] [Google Scholar]
- [77].Reid S, Ryu JK, Kim Y, Jeon BH. The Effects of Fermented Laminaria japonica on Short-Term Working Memory and Physical Fitness in the Elderly. Evidence-based complementary and alternative medicine. eCAM 2018. https://doi.org/10.1155/2018/8109621 10.1155/2018/8109621 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [78].Danilov A, Kurganova J. Melatonin in Chronic Pain Syndromes. Pain Ther 2016;5:1-17. https://doi.org/10.1007/s40122-016-0049-y 10.1007/s40122-016-0049-y [DOI] [PMC free article] [PubMed] [Google Scholar]
- [79].Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res 2012;52:365-75. https://doi.org/10.1111/j.1600-079X.2011.00962.x 10.1111/j.1600-079X.2011.00962.x [DOI] [PubMed] [Google Scholar]
- [80].Antón-Tay F, Díaz JL, Fernández-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci I 1971;10:841-50. https://doi.org/10.1016/0024-3205(71)90155-x 10.1016/0024-3205(71)90155-x [DOI] [PubMed] [Google Scholar]
- [81].Jacob S, Poeggeler B, Weishaupt JH, Sirén AL, Hardeland R, Bähr M, Ehrenreich H. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res 2002;33:186-7. https://doi.org/10.1034/j.1600-079x.2002.02943.x 10.1034/j.1600-079x.2002.02943.x [DOI] [PubMed] [Google Scholar]
- [82].Weishaupt JH, Bartels C, Pölking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Hüther G, Schneider A, Bach A, Sirén AL, Hardeland R, Bähr M, Nave KA, Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 2006;41:313-23. https://doi.org/10.1111/j.1600-079X.2006.00377.x 10.1111/j.1600-079X.2006.00377.x [DOI] [PubMed] [Google Scholar]
- [83].Chahbouni M, Escames G, López LC, Sevilla B, Doerrier C, Muñoz-Hoyos A, Molina-Carballo A, Acuña-Castroviejo D. Melatonin treatment counteracts the hyperoxidative status in erythrocytes of patients suffering from Duchenne muscular dystrophy. Clin Biochem 2011;44:853-8. https://doi.org/10.1016/j.clinbiochem.2011.04.001 10.1016/j.clinbiochem.2011.04.001 [DOI] [PubMed] [Google Scholar]
- [84].López-González A, Álvarez-Sánchez N, Lardone PJ, Cruz-Chamorro I, Martínez-López A, Guerrero JM, Reiter RJ, Carrillo-Vico A. Melatonin treatment improves primary progressive multiple sclerosis: a case report. J Pineal Res 2015;58:173-7. https://doi.org/10.1111/jpi.12203 10.1111/jpi.12203 [DOI] [PubMed] [Google Scholar]
- [85].Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004;63:757. https://doi.org/10.1212/01.wnl.0000134653.35587.24 10.1212/01.wnl.0000134653.35587.24 [DOI] [PubMed] [Google Scholar]
- [86].Kiecolt-Glaser JK, Belury MA, Andridge R, Malarkey WB, Glaser R. Omega-3 supplementation lowers inflammation and anxiety in medical students: a randomized controlled trial. Brain Behav Immun 2011;25:1725-34. https://doi.org/10.1016/j.bbi.2011.07.229 10.1016/j.bbi.2011.07.229 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [87].Mattson MP. Diet – Brain Connections. Impact on Memory, Mood, Aging and Disease, 1st Edition. New York: Springer; 2022. https://doi.org/10.1007/978-1-4615-1067-3 10.1007/978-1-4615-1067-3 [DOI] [Google Scholar]
- [88].Dangour AD, Allen E, Elbourne D, Fletcher A, Richards M, Uauy R. Fish consumption and cognitive function among older people in the UK: baseline data from the OPAL study. J Nutr Health Aging 2009;13:198-202. https://doi.org/10.1007/s12603-009-0057-2 10.1007/s12603-009-0057-2 [DOI] [PubMed] [Google Scholar]
- [89].da Silva TM, Munhoz RP, Alvarez C, Naliwaiko K, Kiss A, Andreatini R, Ferraz AC. Depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 2008;111:351-9. https://doi.org/10.1016/j.jad.2008.03.008 10.1016/j.jad.2008.03.008 [DOI] [PubMed] [Google Scholar]
- [90].Otsuka M, Yamaguchi K, Ueki A. Similarities and differences between Alzheimer’s disease and vascular dementia from the viewpoint of nutrition. Ann N Y Acad Sci 2002;977:155-6. https://doi.org/10.1111/j.1749-6632.2002.tb04811.x 10.1111/j.1749-6632.2002.tb04811.x [DOI] [PubMed] [Google Scholar]
- [91].Kennedy DO. B vitamins and the brain: mechanisms dose and efficacy – a review. Nutrients 2016;8:68. https://doi.org/10.3390/nu8020068 10.3390/nu8020068 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [92].Sechi G, Sechi E, Fois C, Kumar N. Advances in clinical determinants and neurological manifestations of B vitamin deficiency in adults. Nutr Rev 2016;74:281-300. https://doi.org/10.1093/nutrit/nuv107 10.1093/nutrit/nuv107 [DOI] [PubMed] [Google Scholar]
- [93].Smith AD, Refsum H, Bottiglieri T, Fenech M, Hooshmand B, McCaddon A, Miller JW, Rosenberg IH, Obeid R. Homocysteine and dementia: an international consensus statement. Alzheimers Dis 2018;62:561-70. https://doi.org/10.3233/JAD-171042 10.3233/JAD-171042 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [94].Bonke D, Nickel B. Improvement of fine motoric movement control by elevated dosages of vitamin B1, B6, and B12 in target shooting. Int J Vitam Nutr Res Suppl 1989;30:198-204. [PubMed] [Google Scholar]
- [95].Calderón-Ospina CA, Nava-Mesa MO. B Vitamins in the nervous system: Current knowledge of the biochemical modes of action and synergies of thiamine, pyridoxine, and cobalamin. CNS Neurosci Ther 2020;26:5-13. https://doi.org/10.1111/cns.13207 10.1111/cns.13207 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [96].Langan RC, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. Am Fam Physician 2017;96:384-9. [PubMed] [Google Scholar]
- [97].Martin PR. Molecular mechanisms of thiamine utilization. Curr Mol Med 2001;1:197-207. https://doi.org/10.2174/1566524013363870 10.2174/1566524013363870 [DOI] [PubMed] [Google Scholar]
- [98].Zempleni J, Suttie JW, Gregory JF, III, Stover PJ, eds. Handbook of vitamins. CRC Press; 2013;29. https://doi.org/10.1201/b15413 10.1201/b15413 [DOI] [Google Scholar]
- [99].Kumar N. Neurologic aspects of cobalamin (B12) deficiency. Handb Clin Neurol 2014;120:915-26. https://doi.org/10.1016/B978-0-7020-4087-0.00060-7 10.1016/B978-0-7020-4087-0.00060-7 [DOI] [PubMed] [Google Scholar]
- [100].Momosaki K, Kido J, Matsumoto S, Taniguchi A, Akiyama T, Sawada T, Ozasa S, Nakamura K. The Effect of S-Adenosylmethionine Treatment on Neurobehavioral Phenotypes in Lesch-Nyhan Disease: A Case Report. Case Rep Neurol 2019;11:256-64. https://doi.org/10.1159/000502568 10.1159/000502568 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [101].Silveri MM, Parow AM, Villafuerte RA, Damico KE, Goren J, Stoll AL, Cohen BM, Renshaw PF. S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biol Psychiatry 2003;54:833-9. https://doi.org/10.1016/s0006-3223(03)00064-7 10.1016/s0006-3223(03)00064-7 [DOI] [PubMed] [Google Scholar]
- [102].Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med 2005;28:132-9. [PubMed] [Google Scholar]
- [103].Sood A, Prasad K, Croghan IT, Schroeder DR, Ehlers SL, Ebbert JO. S-adenosyl-L-methionine (SAMe) for smoking abstinence: a randomized clinical trial. J Altern Complement Med 2012;18:854-9. https://doi.org/10.1089/acm.2011.0462 10.1089/acm.2011.0462 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [104].Di Rocco A, Rogers JD, Brown R, Werner P, Bottiglieri T. S-Adenosyl-Methionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord 2000;15:1225-9. https://doi.org/10.1002/1531-8257(200011)15:6<1225::aid-mds1025>3.0.co;2-a [DOI] [PubMed] [Google Scholar]
- [105].Sarris J, Thomson R, Hargraves F, Eaton M, de Manincor M, Veronese N, Solmi M, Stubbs B, Yung AR, Firth J. Multiple lifestyle factors and depressed mood: a cross-sectional and longitudinal analysis of the UK Biobank (N = 84,860). BMC Med 2020;18:354. https://doi.org/10.1186/s12916-020-01813-5 10.1186/s12916-020-01813-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [106].Buist R. The therapeutic predictability of tryptophan and tyrosine in the treatment of depression. Int J Clin Nutr Rev 1983;3:1-3. [Google Scholar]
- [107].De Luca V, Viggiano E, Messina G, Viggiano A, Borlido C, Viggiano A, Monda M. Peripheral amino Acid levels in schizophrenia and antipsychotic treatment. Psychiatry Investig 2008;5:203-8. https://doi.org/10.4306/pi.2008.5.4.203 10.4306/pi.2008.5.4.203 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [108].Green AR, Aronson JK, Cowen PJ. The pharmacokinetics of L-tryptophan following its intravenous and oral administration. Br J Clin Pharmacol 1985;20:317-21. https://doi.org/10.1111/j.1365-2125.1985.tb05070.x 10.1111/j.1365-2125.1985.tb05070.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- [109].Ozawa M, Ninomiya T, Ohara T, Hirakawa Y, Doi Y, Hata J, Uchida K, Shirota T, Kitazono T, Kiyohara Y. Self-reported dietary intake of potassium, calcium, and magnesium and risk of dementia in the Japanese: the Hisayama Study. J Am Geriatr Soc 2012;60:1515-20. https://doi.org/10.1111/j.1532-5415.2012.04061.x 10.1111/j.1532-5415.2012.04061.x [DOI] [PubMed] [Google Scholar]
- [110].Barbagallo M, Belvedere M, Di Bella G, Dominguez LJ. Altered ionized magnesium levels in mild-to-moderate Alzheimer’s disease. Magnes Res 2011;24:S115-21. https://doi.org/10.1684/mrh.2011.0287 10.1684/mrh.2011.0287 [DOI] [PubMed] [Google Scholar]
- [111].Muir KW, Lees KR, Ford I, Davis SIntravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004;363:439-45. https://doi.org/10.1016/S0140-6736(04)15490-1 10.1016/S0140-6736(04)15490-1 [DOI] [PubMed] [Google Scholar]
- [112].Morris G, Gamage E, Travica N, Berk M, Jacka FN, O’Neil A, Puri BK, Carvalho AF, Bortolasci CC, Walder K, Marx W. Polyphenols as adjunctive treatments in psychiatric and neurodegenerative disorders: Efficacy, mechanisms of action, and factors influencing inter-individual response. Free Radic Biol Med 2021;172:101-22. https://doi.org/10.1016/j.freeradbiomed.2021.05.036 10.1016/j.freeradbiomed.2021.05.036 [DOI] [PubMed] [Google Scholar]
- [113].Hemanth Kumar B, Arun Reddy R, Mahesh Kumar J, Dinesh Kumar B, Diwan PV. Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. Can J Physiol Pharmacol 2017;95:32-42. https://doi.org/10.1139/cjpp-2016-0147 10.1139/cjpp-2016-0147 [DOI] [PubMed] [Google Scholar]
- [114].de Oliveira NG, Teixeira IT, Theodoro H, Branco CS. Dietary total antioxidant capacity as a preventive factor against depression in climacteric women. Dement Neuropsychol 2019;13:305-11. https://doi.org/10.1590/1980-57642018dn13-030007 10.1590/1980-57642018dn13-030007 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [115].Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158-68. https://doi.org/10.5414/cpp40158 10.5414/cpp40158 [DOI] [PubMed] [Google Scholar]
- [116].Verlaet AA, Ceulemans B, Verhelst H, Van West D, De Bruyne T, Pieters L, Savelkoul HF, Hermans N. Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial. Trials 2017;18:145. https://doi.org/10.1186/s13063-017-1879-6 10.1186/s13063-017-1879-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [117].Lorenzo JM, Putnik P, Kovačević DB, Petrović M, Munekata PE, Gómez B, Marszałek K, Roohinejad S, Barba FJ. Silymarin compounds: Chemistry, innovative extraction techniques and synthesis. Stud Nat Prod Chem 2020;64:111-30. https://doi.org/10.1016/B978-0-12-817903-1.00004-8 10.1016/B978-0-12-817903-1.00004-8 [DOI] [Google Scholar]
- [118].Haddadi R, Shahidi Z, Eyvari-Brooshghalan S. Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms. Phytomedicine 2020;79:153320. https://doi.org/10.1016/j.phymed.2020.153320 10.1016/j.phymed.2020.153320 [DOI] [PubMed] [Google Scholar]
- [119].Devi KP, Malar DS, Braidy N, Nabavi SM, Nabavi SF. A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin. Current Drug Targets 2017;18:1529-36. https://doi.org/10.2174/1389450117666161227125121 10.2174/1389450117666161227125121 [DOI] [PubMed] [Google Scholar]
- [120].Guo H, Cao H, Cui X, Zheng W, Wang S, Yu J, Chen Z. Silymarin’s inhibition and treatment effects for Alzheimer’s disease. Molecules 2019;24:1748. https://doi.org/10.3390/molecules24091748 10.3390/molecules24091748 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [121].Lopresti AL. Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies. J Psychopharmacol 2017;31:287-302. https://doi.org/10.1177/0269881116686883 10.1177/0269881116686883 [DOI] [PubMed] [Google Scholar]
- [122].Fusar-Poli L, Vozza L, Gabbiadini A, Vanella A, Concas I, Tinacci S, Petralia A, Signorelli MS, Aguglia E. Curcumin for depression: a meta-analysis. Crit Rev Food Sci Nutr 2020;60:2643-53. https://doi.org/10.1080/10408398.2019.1653260 10.1080/10408398.2019.1653260 [DOI] [PubMed] [Google Scholar]
- [123].Zhu LN, Mei X, Zhang ZG, Xie YP, Lang F. Curcumin intervention for cognitive function in different types of people: A systematic review and meta-analysis. Phytother Res 2019;33:524-33. https://doi.org/10.1002/ptr.6257 10.1002/ptr.6257 [DOI] [PubMed] [Google Scholar]
- [124].Voulgaropoulou SD, Van Amelsvoort TA, Prickaerts J, Vingerhoets C. The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies. Brain Res 2019;1725:146476. https://doi.org/10.1016/j.brainres.2019.146476 10.1016/j.brainres.2019.146476 [DOI] [PubMed] [Google Scholar]
- [125].Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation 2017;14:1-0. https://doi.org/10.1186/s12974-016-0779-0 10.1186/s12974-016-0779-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [126].Komorowska J, Wątroba M, Szukiewicz D. Review of beneficial effects of resveratrol in neurodegenerative diseases such as Alzheimer’s disease. Adv Med Sci 2020;65:415-23. https://doi.org/10.1016/j.advms.2020.08.002 10.1016/j.advms.2020.08.002 [DOI] [PubMed] [Google Scholar]
- [127].Mattioli R, Francioso A, Mosca L, Silva P. Anthocyanins: A comprehensive review of their chemical properties and health effects on cardiovascular and neurodegenerative diseases. Molecules 2020;25:3809. https://doi.org/10.3390/molecules25173809 10.3390/molecules25173809 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [128].Zaplatic E, Bule M, Shah SZ, Uddin MS, Niaz K. Molecular mechanisms underlying protective role of quercetin in attenuating Alzheimer’s disease. Life Sci 2019;224:109-19. https://doi.org/10.1016/j.lfs.2019.03.055 10.1016/j.lfs.2019.03.055 [DOI] [PubMed] [Google Scholar]
- [129].Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, Liu H, Yin Y. Quercetin, Inflammation and Immunity. Nutrients 2016;8:167. https://doi.org/10.3390/nu8030167 10.3390/nu8030167 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [130].Banerjee S, Anand U, Ghosh S, Ray D, Ray P, Nandy S, Deshmukh GD, Tripathi V, Dey A. Bacosides from Bacopa monnieri extract: An overview of the effects on neurological disorders. Phytother Res 2021;35:5668-79. https://doi.org/10.1002/ptr.7203 10.1002/ptr.7203 [DOI] [PubMed] [Google Scholar]
- [131].Dar NJ. MuzamilAhmad. Neurodegenerative diseases and Withania somnifera (L.): An update. J Ethnopharmacol 2020;256:112769. https://doi.org/10.1016/j.jep.2020.112769 10.1016/j.jep.2020.112769 [DOI] [PubMed] [Google Scholar]
- [132].Sharma V, Sharma R, Gautam DS, Kuca K, Nepovimova E, Martins N. Role of Vacha (Acorus calamus Linn.) in Neurological and Metabolic Disorders: Evidence from Ethnopharmacology, Phytochemistry, Pharmacology and Clinical Study. J Clin Med 2020;9:1176. https://doi.org/10.3390/jcm9041176 10.3390/jcm9041176 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [133].Simpson T, Pase M, Stough C. Bacopa monnieri as an Antioxidant Therapy to Reduce Oxidative Stress in the Aging Brain. Evid Based Complement Alternat Med 2015;2015:615384. https://doi.org/10.1155/2015/615384 10.1155/2015/615384 [DOI] [PMC free article] [PubMed] [Google Scholar]
- [134].Mishra S, Srivastava S, Tripathi RD, Govindarajan R, Kuriakose SV, Prasad MN. Phytochelatin synthesis and response of antioxidants during cadmium stress in Bacopa monnieri L. Plant Physiol Biochem 2006;44:25-37. https://doi.org/10.1016/j.plaphy.2006.01.007 10.1016/j.plaphy.2006.01.007 [DOI] [PubMed] [Google Scholar]
- [135].Rasool M, Malik A, Qureshi MS, Manan A, Pushparaj PN, Asif M, Qazi MH, Qazi AM, Kamal MA, Gan SH, Sheikh IA. Recent updates in the treatment of neurodegenerative disorders using natural compounds. Evid Based Complement Alternat Med 2014;2014:979730. https://doi.org/10.1155/2014/979730 10.1155/2014/979730 [DOI] [PMC free article] [PubMed] [Google Scholar]